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Research in the last few years has
revealed a sophisticated interaction net-
work between multiple bone marrow
cells that regulate different hematopoi-
etic stem cell (HSC) properties such
as proliferation, differentiation, localiza-
tion, and self-renewal during homeosta-
sis. These mechanisms are essential to
keep the physiological HSC numbers in
check and interfere with malignant pro-
gression. In addition to the identification
of multiple mutations and chromosomal
aberrations driving the progression of my-
eloid malignancies, alterations in the niche
compartment recently gained attention for
contributing to disease progression. Leu-
kemic cells can remodel the niche into a
permissive environment favoring leukemic
stem cell expansion over normal HSC
maintenance, andevidence is accumulating
that certain niche alterations can even
induce leukemic transformation. Relapse
after chemotherapy isstill amajor challenge
during treatment of myeloid malignancies,
and cure is only rarely achieved. Recent
progress in understanding the niche-
imposedchemoresistancemechanismswill
likely contribute to the improvement of
current therapeutic strategies. This article
discusses the role of different niche cells
and their stage- and disease-specific roles
during progression of myeloid malignan-
cies and in response to chemotherapy.
(Blood. 2017;129(7):811-822)
Introduction
Myeloid malignancies are clonal hematopoietic disorders characterized
by excessive proliferation, abnormal self-renewal, and/or differentiation
defects of hematopoietic stem cells (HSCs) and myeloid progenitor
cells. They mainly consist of myeloproliferative neoplasms (MPNs),
myelodysplastic syndrome (MDS), and acute myeloid leukemia
(AML), caused by different genetic and epigenetic changes in HSCs
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and functional changes in bonemarrow (BM) niche cells. Genetic and
epigenetic modiﬁcations have also been noted in BM mesenchymal
stromal cells (BMSCs) in MDS and AML. The end results of these
alterations are phenotypically distinct diseases that likely require the
design of speciﬁc treatments. However, the use of selective inhibitors
is challenging, because they sometimes also affect the normal
hematopoietic counterparts, and clones carrying othermutations often
cause relapse after chemotherapy. In this case, overcoming
common mechanisms of resistance might be more likely to succeed
therapeutically.
The World Health Organization subdivided MPNs into four
distinct diseases: chronic myelogenous leukemia (CML), character-
ized by the BCR-ABL oncogene fusion (Philadelphia chromosome
[Ph1]) protein and the three Ph– disorders named polycythemia vera
(PV), essential thrombocythemia (ET), and primary myeloﬁbrosis
(PMF).1 Whereas PV is primarily associated with high erythrocyte
counts, patients with ET have high platelet counts, and PMF is mainly
related to BM failure as a result of ﬁbrotic BM degeneration. These
different clinical symptoms suggest that each MPN subtype is an
independent disease, but transitions among them are observed in some
patients.
Alterations of BM niches contribute to the
progression of myeloid malignancies
Streaming from the discovery of driver mutations, myeloid malignan-
cies were initially regarded as primarily driven by leukemic cell–
autonomous mechanisms. However, cumulative evidence indicates
that leukemic cells can exploit physiological niche signals and can
overcome control by the normal microenvironment and/or remodel
BM niches into permissive/self-reinforcing environments that support
disease progression at the expense of normal hematopoiesis.
During leukemogenesis, malignant clones become progressively
independent of niche-imposed physiological control mechanisms.
In early leukemogenesis, BM homing and spatial localization
of early leukemic stem cells (LSCs), which are also called pre-
LSCs, are similar to that of normal HSCs. However, at later stages,
LSCs home similarly to committed progenitors and become pro-
gressively independent of microenvironmental WNT signals.2
Some LSC alterations can simultaneously stimulate proliferation
and myeloid skewing without affecting self-renewal. For instance,
reduced JunB expression observed in many myeloid malignancies
diminishes the responsiveness of LSCs to Notch and transforming
growth factor b (TGF-b) niche signals.3 LSCs can become pro-
gressively insensitive to TGF-b during disease evolution from
chronic to acute leukemia.4
The ﬁrst indications of microenvironmental contribution to
myeloid malignancies derive from reciprocal BM transplantation
experiments showing that myeloid malignancies can arise from
originally nonmutated hematopoietic cells in an altered microenvi-
ronment. For instance, MPN-like disease is observed in mice carrying
a constitutive nonhematopoietic retinoic acid receptor g deletion.5
MPN-like disease also develops after combined retinoblastoma
protein deletion in nonhematopoietic and myeloid cells.6,7 Similarly,
Notch pathway inhibition by the deletion of ubiquitin E3 ligase Mind
bomb 1 (Mib1) in nonhematopoietic cells causes nontransplantable
MPN-like disease, which can be reverted by microenvironmental
Notch activation.8 Altogether, these pioneering studies represent
strong evidence that the microenvironment exerts more than a mere
bystander effect in myeloid malignancies.
Role of the BM vasculature
Several myeloid malignancies, including AML, MPN, and MDS, have
been correlated with increased BM angiogenesis.9-13 BM vasculariza-
tion in MPN patients correlates with janus kinase (JAK2) allele burden
and stage, being highest in PMF, followed by CML, PV, and ET
patients.11,12,14 MDS is characterized by lower vascularization, but
blood vessel density similarly increaseswith disease aggressiveness and
speciﬁcally correlates with progression to ﬁbrosis.13,15 In addition to the
increased vascular density, BM vessel morphology is disorganized and
irregular inMPNandAML.11,16Hence, increased anddisorganizedBM
vascularization is a common niche alteration of myeloid malignancies.
Progression of myeloid malignancies is supported by synergistic
crosstalk betweenmalignant blasts and endothelial cells (ECs).Enhanced
BM vascularization correlates with upregulation of angiogenic factors,
including vascular endothelial growth factor (VEGF)–Aand interleukins
(ILs).10,12,17-20 Whereas blasts secrete proangiogenic molecules, ECs
releaseangiocrine factors that promoteblast survival andproliferation.9,17
Blast-derived angiogenic factors act in a paracrine manner and
also stimulate leukemic cell survival and proliferation via autocrine
pathways.19,21,22 Similar to solid tumors, leukemic cells produce the
key proangiogenic factor VEGF-A, which stimulates angiogenesis by
paracrine mechanisms and increases blast survival and proliferation via
autocrine VEGFR2-dependent pathways.17,19,21,23 Endothelial VEGF
signaling stimulates blood vessel formation and also induces angiocrine
factor (such as granulocyte-macrophage colony-stimulating factor
[GM-CSF], macrophage CSF [M-CSF], granulocyte CSF [G-CSF],
IL-6, andstemcell factor)production inECs,whichpromotesproliferation
of malignant cells (Figure 1).24-26 VEGF-dependent EC activation
similarly increases EC-AML cell adhesion and AML aggressiveness.26
Leukemic cell–derived proangiogenic and proinﬂammatory factors
such as IL-1b and basic ﬁbroblast growth factor (bFGF) can stimulate
ECs to release VEGF-C, thereby supporting blast survival and
proliferation.22 Megakaryocytes represent an alternative VEGF
source in MDS and might also stimulate angiogenesis in ET and
PMF.13 High VEGF-A and VEGF-C plasma concentrations are
associated with adverse prognosis in AML and CML, and VEGF-A
levels correlate with MPN disease stage (PMF.PV.ET).10-12,18,27
TargetingVEGFsignalingwithbevacizumabhasnotbeen successful so
far, but adjuvant treatment with different tyrosine kinase inhibitors
(TKIs) in AML and MPN might normalize the microenvironment and
eradicate malignant cells. However, patient response to therapy is
heterogeneous and identifying susceptible subgroups is crucial.18,28-30
The angiopoietin 1 (ANG)/TIE signaling system—a master
regulator of solid tumor angiogenesis—is also gaining recognition in
myeloid malignancies. High ANG2 levels in AML patients do not
correlate with changes in vessel density but may be of prognostic value
because they correlate with improved survival when VEGF expression
is low.31-33AbnormalANG/TIE signaling has beendetected inECs and
also in leukemic cells.34,35 Autocrine ANG1/TIE2 signaling in blasts
induces signal transducer andactivator of transcription1 (STAT1)/3/5/6
and ERK pathways, which support leukemic cell proliferation,34,36 and
TIE2/IP-3 kinase signaling increases AML cell survival.35
Other proangiogenic factors such as bFGF and HGF are also
upregulated in AML, CML, and MDS.10 Likewise, proinﬂammatory
cytokines, including tumor necrosis factora (TNF-a), IL-6, and IL-1b,
are increased when AML blasts are cocultured with ECs. These
cytokines stimulate EC proliferation and G-CSF and GM-CSF
production, thereby promoting leukemic cell expansion.25,37 Secretion
of TNF-a and IL-1b by AML blasts upregulates endothelial adhesion
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receptors such as selectins VCAM-1 and ICAM-1 to support vascular
adhesion and proliferation.38ECactivation by inﬂammatory cytokines
might compromise vascular integrity and favor thrombosis, further
aggravating the proinﬂammatory environment.
Alterations in ECs might be a predisposing factor for the develop-
ment of myeloid malignancies. MPN-like disease has also been
observed in response to deletion of endothelial-speciﬁc Rbpj.39 Loss of
endothelial Notch signaling upregulates microRNA 155 (miR-155),
which de-represses nuclear factor kB (NF-kB) leading to G-CSF and
TNF-a overexpression andmyeloid expansion. The potential relevance
of this pathway is emphasized by an increased miR-155 level in human
PMF BM.39 CML cells and ECs also communicate via exosomes by
shuttling miR-126 to downregulate VCAM-1 and CXCL12 in ECs
and decrease CML adhesion and migration.40
Despite the release of multiple proangiogenic factors in the tumor
microenvironment, hypoxia represents a common feature of myeloid
malignancies and can inﬂuence LSC cycling, quiescence, differenti-
ation, metabolism, and chemotherapy resistance. However, the role
of hypoxia and downstream hypoxia-inducible factor 1a (HIF-1a)
signaling in leukemia remains controversial, with published evidence
for both supporting and inhibitory roles. In some studies, hematopoietic
HIF-1a deletion promotes AML and MPN progression in mice.41,42
Similarly, combined deletion of HIF-1a and HIF-2a can accelerate
AML initiation, but it is dispensable for disease maintenance.43 In
contrast, other studies indicate that HIF-1a and HIF-2a support LSC
survival by inducing p16 and p19 signaling and reducing reactive
oxygen species (ROS) levels and endoplasmic reticulum stress,
respectively.44,45 Hypoxia-induced VEGF production in a mouse
model of CML correlates with increased clonogenicity, maintenance,
repopulation capacity, and TKI resistance of BCR-ABL1 cells.46
Cytarabine and doxorubicin resistance is partly conferred by HIF-1a
signaling, which induces quiescence in AML subclones by interfering
with apoptosis and supporting survival signaling.47,48 Hypoxia might
also favor leukemogenic niche metabolism and cytokine secretion.
In addition to hypoxia, cytokines, interferon alfa, hormones, and genetic
modiﬁcations can stimulate HIF-1a signaling, and their deregulation in
a leukemic niche might similarly control this pathway in a hypoxia-
independent manner.49 HIF-1amight be a prognostic marker for high-
risk AML and CML patients and a valuable therapeutic target. These
divergent results on the role of hypoxia in the LSC niche call for
further studies on this particular aspect of environmental control.
Intense morphologic and functional remodeling of BM vessels has
been observed in myeloid malignancies and generally result in in-
creased but dysfunctional vasculature.A synergistic crosstalk is establi-
shed between ECs and leukemic cells, which stimulates the growth
of both. Increased permeability of an activated endothelium might
also favor adhesion andmobilization of both inﬂammatory and leukemic
cells, further aggravating inﬂammation, invasion of peripheral organs,
and resistance (discussed below).
Role of BMSCs
Although initial in vitro studies did not observe major alterations in
BMSCs, recent in vivo characterization has identiﬁed BMSCs as
essential components of theHSCniche that are deregulated in adisease-
speciﬁc manner in myeloid malignancies. The niche might have
disparate roles in various myeloid malignancies, and these roles might
also change during disease evolution (Figure 2).
The ﬁrst evidence of a possible role for BMSCs in myeloid malignan-
cies arose from studies that identiﬁed chromosomal abnormalities such as
hypodiploidy and chromosomal translocations, duplications, and deletions
in hematopoietic cells of patients with myeloid malignancies and also in
BMSCs.50-56 These cytogenetic abnormalities have been observed in 30%
to 70% of the BMSCs from patients withMDS or AML and are different
from hematopoietic mutations in the same individuals.50,52 Yet stro-
mal genomic alterations are associated with unfavorable prognostic
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Figure 1. Role of BM blood vessels in myeloid malignancies. Angiogenesis increases during progression of myeloid malignancies and is particularly associated with
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chromosomal abnormalities in hematopoietic cells.51,52 Likewise, 55%
of the BMSCs from patients with MDS showed abnormal karyotypes,
and 57%of the BMSCs from patients withAMLwho had trisomy 8 and
monosomy 7 in hematopoietic cells showed cytogenetic aberrations.54
Similarly, trisomy 8mosaicism is associated with increased incidence
of myeloid leukemia and MDS, and stromal cells in these patients
favor leukemic cell proliferation.57 Chromosomal and epigenetic
abnormalities inBMSCs frompatientswithMDSandAMLhave been
linked to certain disease subtypes and distinctive gene-expression
programs.53,56,58 These genetic abnormalities in BMSCs suggest
enhanced genetic susceptibility and an active role of BMSCs in the
progression of MDS or AML.
The functional consequences of these BMSC alterations are still
debated. Several studies have noted normal differentiation, adhesion,
expressionand survival and theability to support hematopoiesis exvivo in
BMSCs frompatientswithMDS,CML, orAML.50-52,54,59-62 In contrast,
other studies showed abnormal differentiation, defective hematopoietic
supportive capacity, reduced expression of adhesionmolecules, increased
apoptosis, and increased production of IL-1b and stem cell factor in
BMSCs of patients with myeloid malignancies.55,56,63-75
These in vitro studies proposed some divergent views on BMSC
alterations and contributions to disease, but more recent in vivo studies
on several myeloid malignancies have reported altered BMSC growth
and differentiation and the production of cytokine and HSC retention
factor.Whether these BMSC alterationswere predisposing or initiating
factors for disease has remained elusive so far. The ﬁrst evidence that
alterations of BMSCs can drive myeloid malignancies arose from the
deletion of the RNA processing enzyme Dicer1 in osteoprogenitor
cells, which caused MDS-like disease with sporadic transformation to
AML. The disease could be reverted by transplanting leukemic cells
from mice with Dicer1-deleted osteoprogenitors into wild-type mice.
Loss ofDICER1 in osteoprogenitor cells (but not inmature osteoblasts)
resulted in downregulation of the ribosome maturation protein SBDS,
which ismutated in humanShwachman-Bodian-Diamond syndrome and
is associated with congenital BM failure and leukemic predisposition.76
Reduced expression of DICER, DROSHA, and SBDS has been noted in
BMSCs from patients with MDS,77 emphasizing the potential clinical
relevance of these ﬁndings. A recent study has provided mechanistic
insight on genotoxic stress caused by mutations in BMSCs, which can
impair normal hematopoiesis and favor leukemogenesis. Loss of Sbds in
BMSCs in mice recapitulates the characteristic osteoporosis found in
humanShwachman-Bodian-Diamondsyndrome. It also stimulatesBMSC
p53 signaling and secretion of the inﬂammatory molecules S100A8 and
S100A9. S100A8/A9 activates toll-like receptor 4 on normal hematopoi-
etic stem and progenitor cells (HSPCs), which leads to inﬂammatory
damage, including hyperpolarized mitochondria, which triggers in-
creased ROS production and DNA double-strand breaks. The potential
relevance of niche S100A8/A9 expression in human leukemogenesis is
emphasized by the correlation of S100A8/A9 expression in BMSCs and
bone lining cells and the leukemic evolution of patients with MDS.78
Patients with Noonan syndrome often carry a mutation in the RAS
signaling mediator PTPN11 and are at increased risk for developing
childhood MPNs. A recent study has now shown that leukemogenic
effects of activating PTPN11mutations are not solely hematopoietic cell
autonomous, but thatPTPN11mutations inBMSCs and osteoprogenitor
cells can similarly drive MPN progression. Excessive CCL3 production
by PTPN11-activated BMSCs results in the recruitment of monocytes
to BMSCs, which hyperactivate HSCs by secreting inﬂammatory
cytokines, including IL-1b, thereby exacerbating disease progression.79
Recent studies using mouse models of CML, MPNs, and AML
demonstrate that speciﬁc BMSC-leukemic cell interactions are
important for leukemogenesis (Table 1).16,80,81 In an inducible
BCR-ABL mouse model, CML cells support BMSC proliferation
and abnormal differentiation, which generate functionally altered and
inﬂammatory osteoblasts. BMSCs in CML failed to maintain normal
HSCs because of reduced Cxcl12 expression, favoring the expansion
of less niche-dependent LSCs. Osteoblastic cells in CML secrete
proinﬂammatory cytokines (IL-1b and TNF-a) that amplify disease
progression by triggering myeloid cell proliferation and creating a
self-reinforcing niche.81 CML cells also instruct BMSCs to secrete
PIGF,which stimulates angiogenesis and promotesCMLproliferation
and metabolism, in part independently of BCR-ABL1 signaling.82
Progression of Ph– MPN also disrupts normal BMSC function, thus
promoting disease progression. Proinﬂammatory cytokines produced by
JAK2V617Fhematopoieticcells, suchas IL-1b, cancause localneuropathy
and microenvironmental damage that leads to disease manifestation. In
this inﬂammatory environment, MPN-associated neuropathy sensitizes
nestin1 BMSCs to undergo apoptosis and reduces their HSC niche
properties (includingCxcl12 expression). Genetic depletion of nestin1
cells can worsen myeloﬁbrosis and thrombocytosis, which is also
observed in mice lacking the b3-adrenergic receptor. In contrast,
neural protection by neurotrophic factors or neural stimulation of the
microenvironment by chronic treatment with b3-adrenergic agonists
rescues nestin1 cells and improves Cxcl12 and IL-1b expression,
neutrophilia, thrombocytosis, and myeloﬁbrosis.80
Similar neuropathy-drivenmicroenvironmental deregulation has been
reported in AML.16 Yet the neuropathy might be comparatively less
relevant in AML because neural interventions did not signiﬁcantly affect
leukemogenesis in that study.Whether neuropathy-drivenmicroenviron-
mental changes are more broadly relevant in other hematologic
malignancies remains to be investigated.
Reciprocal leukemic-niche interactions have also been highlighted
in MDS. On one hand, patient-derived MDS cell engraftment is
dependent on niche factors, such as LIF, VEGF, IGF-BP2, and
N-cadherin. On the other hand, exposure of normal BMSCs to MDS
renders them malignant-like, which highlights MDS-induced BMSC
reprogramming.83 Alterations ofWNT signaling in BMSCs have been
associated with defective BMSC proliferation in MDS,84,85 partially
because of the induction of senescence.86
Communication between BMSCs and MDS cells is partly medi-
ated by extracellular vesicles.87 Exosome-mediated crosstalk between
CML cells and human BMSCs triggers IL-8–dependent survival.88,89
Similarly, primary leukemic cells and cell lines release microvesicles
containingRNAs that alter the secretion of niche-reprograming factors.90
Together, these studies highlight the role of BMSCs as key elements
ofpredisposition,manifestation, andevolutionofmyeloidmalignancies.
Whereas functionally or genetically altered BMSCs increase inﬂam-
mation and genotoxic stress, mutated hematopoietic cells critically
compromise the normal function of BMSCs in the HSC niche,
hampering normal hematopoiesis and favoring leukemogenesis.
Whether these changes in BMSCs initiate disease in humans and/or
select for particular mutated clones is a subject of intense research.
Anchoring of myeloid leukemic cells to
their niches
Adhesionmolecules are important for LSC engraftment and interaction
with the niche. CD44 is a glycoprotein receptor for hyaluronan,
selectins, and osteopontin. A specialized glycoform of CD44 named
HCELL is a BMhoming receptor.91 CD44 is overexpressed inCML,92
and homing and engraftment of CML and AML LSCs to their BM
niches ismuchmore dependent onCD44 comparedwith normal HSCs
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or B-cell acute lymphoblastic leukemia cells. Anti-CD44 treatment
reduces CML incidence and AML burden in xenografts.93,94 In
addition to directing LSC homing, CD44 also maintains LSCs in
a primitive state,94,95 and high CD44 levels correlate with AML
induction and relapse in AML mouse models.96,97
CD44 is a potent E-selectin receptor in CML, and E-selectin
blockade can also reduce LSC numbers in CML.98 E-selectin is
overexpressed on BM endothelium in AML, and antagonizing
E-selectin can sensitize AML cells to chemotherapy.99 CD44
cooperates with other adhesion molecules, such as CD49d100 and
integrin b1, which inhibit CML proliferation.101 Treatment with
INF-a can restore impaired integrin b1–mediated adhesion of
CML cells and inhibit their proliferation.102,103 This interaction
might be relevant in other malignancies because integrin b1–
mediated adhesion inﬂuences chemotherapy sensitivity in AML
and increased ﬁbronectin secretion in early ﬁbrotic stages of
MPN.104,105
Downregulation of BM Cxcl12 helps different myeloid
malignancies16,80,106 and correlates with HSPC mobilization and
extramedullary hematopoiesis. GCSF produced by CML cells
decreases Cxcl12 expression by BMSCs and directly impairs
normal hematopoiesis in an inducible BCR-ABL transgenic
model. Long-term LSCs show reduced homing and retention in
the BM because of increased G-CSF and decreased CXCL12
levels.106
Leukemic cells can further highjack normal BM vascular niches
dependent on CXCL12 and E-selectin.107 Activation of CXCL12
receptor CXCR4 in leukemic cells is important for AML cell survival
and BM retention. Neutralizing CXCR4 antibodies decreases human
AML cell numbers in xenografts.108
Table 1. Main niche alterations in different myeloid malignancies
Disease name Alteration
AML Disease phenotype Hyperproliferation and impaired differentiation of HSC and myeloid progenitors
Acute rapidly progressing disease
Genetic LSC alterations Chromosomal translocations, inversions, mutations in NPM1, CEBPA, KIT, RUNX1, FLT-IDT, or epigenetic
factors
Niche alterations Neuropathy correlating with altered microenvironment16
PTH activation in osteoblasts accelerates AML.4
CD44 and E-selectin are important for LSC niche adhesion and maintaining LSC primitive state.94,95,99
b-catenin activation in osteoblasts stimulates Jag1 expression which activates Notch signaling in HSCs to
induce AML.113,114
Ph– MPN Disease phenotype Clonal HSC disorder with hyperproliferation and expansion of myeloid cells
Erythrocythemia (PV), thrombocythemia (ET), BM fibrosis (PMF)
Slow progression, chronic disease stage, possible transformation to AML
Genetic LSC alterations Mutations in JAK2 (PV, ET, PMF), MPL (ET, PMF), CALR (ET, PMF)
Niche alterations LSCs secrete IL-1b, which damages Schwann cells and sympathetic nerve terminals causing early
neuropathy. This results in apoptosis of nestin1 BMSCs, reduces Cxcl12 production, and results in
thrombocytosis and fibrosis.80
Reduced osteoblast numbers at late stage of the disease.112
Inactivation of Notch or deletion of retinoic acid receptor g or retinoblastoma protein can cause niche-induced
MPN.5,6,8
PTPN11 activation in BMSCs induces CCL3-mediated monocyte recruitment and subsequent IL-
1b–dependent HSC hyperactivation driving MPN progression.79
CML Disease phenotype Clonal HSC disorder with hyperproliferation and expansion of myeloid cells
Slow progression, chronic disease stage, possible transformation to AML
Genetic LSC alterations Chromosomal translocation resulting in BCR-ABL gene fusion
Niche alterations CML cells support BMSC proliferation and abnormal differentiation of osteoblasts into inflammatory cells which
secrete proinflammatory cytokines that trigger myeloid progenitor and osteoblast expansion as well as
stromal remodeling. CXCL12 is reduced in BMSCs favoring LSCs at the expense of HSC expansion.81
TGF-b and Notch cause stromal remodeling.81
PTH activation in osteoblasts attenuates CML.4
CML cells instruct BMSCs to secrete PIGF, which stimulates angiogenesis, CML proliferation, and
metabolism.81
CD44/E-selectin-dependent adhesion of LSCs to niche cells93,98
Osteoblast expansion negatively regulates HSC and LSC proliferation.111
MDS Disease phenotype Differentiation defects in HSCs
Pancytopenia, myelodysplasia
Slow progression, chronic disease, possible transformation to AML
Genetic LSC alterations Chromosomal deletions, NUP98-HOXD13 fusion, mutations in RUNX1, CEBPA, EVI1, NPM1, RAS and splice
and methylation factors
Niche alterations Dicer deletion in osteoprogenitors causes MDS.76
Leukemic cells can reprogram BMSCs into BMSCs of a malignant niche, which provide the important niche
factors LIF, VEGF, IGF-BP2 and N-cadherin.83
Abnormal WNT signaling causes proliferation defects in BMSCs because of increased cell senescence.84-86
Increased osteogenic potential of BMSCs110
p53-S100A8/9-TLR inflammatory signaling in BMSCs causes genotoxic stress in HSCs and supports MDS
development.78
PTH, parathyroid hormone; TLR, toll-like receptor.
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Role of osteoblasts
Reduced trabecular bone mass in retinoic acid receptor g– or
retinoblastoma protein–deﬁcient mice correlates with aggravated
MPN, suggesting that endosteal niche alterations can promote MPN
progression.5,6 The role of osteoblasts in leukemiaprogression seems to
be disease speciﬁc, because constitutive parathyroid hormone receptor
activation in osteoblasts increases bone remodeling and attenuates
CML progression but stimulates MLL-AF9 AML progression.
Increased bone remodeling in mice with constitutively active parathy-
roid hormone signaling causes TGF-b release from bone, reducing
LSC proliferation and maintenance in CML but not in AML, probably
because of reduced TGFBR1 expression or higher constitutive
pSMAD2/3 signaling in AML.4 These differences suggest that the
niche or niches might play different roles at various stages of
leukemogenesis and/or in a disease-speciﬁc manner (Figure 2).
The increased osteogenic potential of BMSCs can contribute to
PMF.109 Similarly, increased osteoblastic priming has been observed
in BMSCs from childhood MDS.110 Osteoblasts also expand during
the chronic phase of CML,81 when they negatively regulate normal
and malignant HSC proliferation.111 This is reminiscent of the role of
nestin1 BMSCs in Ph– MPN, in which depletion of nestin1 cells or
theirCxcl12 production can accelerateMPNprogression.80 Therefore,
MPN preleukemic cells seem to retain sensitivity to normal cues from
the microenvironment, and protecting the niche might be beneﬁcial at
this stage. In contrast, during the blast crisis of this disease, which
resembles acute leukemia, osteoblasts are markedly reduced,112
suggesting that osteoblasts are differentially affected in AML and
CML. AML has been associated with increased bone remodeling and
accumulation of osteoblast-primed BMSCs, which do not seem to be
able tomature into osteoblasts, correlating with decreasedmineralized
bone.16
Strikingly, expression of a constitutively activated form ofb-catenin
in osteoblasts might be sufﬁcient for driving AML-like disease.
Activatedb-catenin signaling increases osteoblastic Jagged expression,
leading to aberrant Notch signaling in HSCs. Inhibition of osteoblastic
Notch signaling by Jagged deletion or pharmacologic treatment with
g-secretase inhibitors preventsAMLdevelopment inmice.113 The same
group has shown that 38% of patients with MDS, AML, or MDS with
leukemic transformation have increased nuclear b-catenin in Runx2-
expressing osteoblastic cells associated with increased Notch activity in
CD341 HSPCs.114 Osteoblasts are decreased in patients with MDS or
AML, and osteoblast recovery correlates with better prognosis.115
Overall, this represents another example of potential mechanisms of
niche-driven oncogenesis in myeloid malignancies.
The niche in response to chemotherapy
High-dose chemotherapy (HDC) is used to eradicate leukemic cells in
AML and advanced MDS. Cytotoxic agents can damage the BM
microenvironment and compromise niche function, regeneration, and
maintenance of normal hematopoiesis (Figure 3). Chronic stromal
damagebyHDCismanifestedby reducedBMSCsandCD44expression
in allogenic BM transplantation recipients, which is associated with
slower hematopoietic recovery.116,117 Myelosuppression can cause
endothelial regression that leads to a discontinuous, hemorrhagic
endothelium accompanied by endothelial denudation. Sinusoidal vessels
are particularly sensitive to irradiation, and subsequent EC regeneration
via VEGFR2 signaling is critical for hematopoietic reconstitution.118
Chemotherapy-triggered BM sympathetic neuropathy can lead to loss of
nestin1cells andECs,which interfereswithhematopoietic regeneration.
Neuroprotective agents have been reported to protect nerves from
chemotherapy-induced injury and to support the survival of blood
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Figure 3. Protection of LSCs from chemotherapy by the microenvironment. Chemotherapy eradicates LSCs but at the same time damages multiple cell types of the
niche and triggers subsequent niche regeneration. Prolonged treatment induces the development of resistance mechanisms, some of which are mediated by niche cells,
including BMSCs and ECs. MT, mitochondria; FN, fibronectin.
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vessels and associated nestin1 cells, which leads to accelerated
hematopoietic recovery.119 Osteoblasts are reduced after multiple
rounds of chemotherapy, and osteoprogenitor numbers are decreased
in response to HDC, eventually causing osteopenia.120,121 Adipocyte
accumulation in aplastic BM might compromise niche function by
negatively inﬂuencing hematopoietic recovery after myeloablation.122
Therefore, the damage inﬂicted by chemotherapy in the BM microen-
vironment can interfere with normal hematopoiesis and eventually
result in BM failure.
HSC transplantation used in relapsed or high-riskAMLcan rapidly
induce neoplasia from malignant or premalignant donor HSCs.123 A
dysfunctional host microenvironment resulting from mutations or
HDC might also promote transformation of donor-derived HSCs into
malignant cells. Likewise, growth of LSCs can alter the microenvi-
ronment and compromise normal HSC growth after allogenic HSC
transplantation.
Although multiple LSC-intrinsic mechanisms of chemoresistance
have been described, the microenvironment has recently attracted
attention in protecting LSCs from chemotherapy (Figure 3). Early
coculture studies showed that cytarabine treatment of BMSCs
interferes with apoptosis and enhances survival of AML cells.124,125
BMSC-derived TGF-b1 is amediator of resistance during cytarabine
treatment of AML.126 Another key chemotherapy resistance–
conferring pathway is CXCL12/CXCR4. Chemotherapy upregulates
CXCR4 in AML cells, and imatinib enhances CXCR4 expression in
BCR-ABL1 cells, which results in increased CXCL12/CXCR4 sur-
vival signaling and lodgment into protective niches.127-130 Adjuvant
treatment of AML andCMLwith CXCR4 inhibitors decreases BMSC-
induced survival pathways and sensitizes AML and CML cells to
chemotherapy and imatinib treatment, respectively.127-130 Co-recruitment
of CXCR4 and its downstreammediator Lyn into lipid rafts is another
imatinib-induced chemotherapy resistance mechanism in CML.131 In
fact, pharmacologic targeting of lipid rafts in combination with
CXCR4/TGF-b1 can further sensitize CML cells to therapy.126,131
BMSC-induced CML chemotherapy resistance also occurs via
upregulation of galectin-3, which stimulates leukemic cell prolifera-
tion, protection from apoptosis, and BM lodgment.132 Likewise,
N-cadherin–dependent interaction of stromal and CML cells has been
proposed to activateb-catenin signaling inCMLcells, thereby shielding
leukemic cells from TKI treatment.133 Reciprocal activation of NF-kB
signaling via VCAM-1/very late antigen 4 (VLA-4) interaction occurs
in BMSCs and AML cells, and blockade of stromal NF-kB signaling
can sensitize AML cells to chemotherapy.134 Likewise, leukemic and
stromal cell interaction via VLA-4 and ﬁbronectin interferes with drug-
induced apoptosis. Combined treatment of cocultures with VLA-
4–speciﬁc antibodies and cytarabine improves survival, and patients
with VLA-4–negative AML have a favorable prognosis.135 Human
AML cells preferentially home and engraft in the endosteal BM of
immunodeﬁcient mice where they remainmore quiescent and protected
from chemotherapy.136
ECs can also confer chemotherapy resistance to AML cells, and
blocking VEGFR2 signaling can increase the susceptibility of leukemic
cells to chemotherapy.26,137 Leukemic cell adhesion to the vasculature
has beenproposed to induce quiescence, resistance to chemotherapy, and
relapse.138One study observed that AML cells acquired EC-like features
and integrated into thebloodvesselwhere theycanbecomequiescent and
evade chemotherapeutic treatment.139 Alternatively, ECs can protect
AML cells from chemotherapy by producing high levels of VEGF and
platelet-derived growth factor (PDGF) in response to cytarabine.140
Emerging evidence indicates that BMSCs shield LSCs from therapy
by affecting their energy metabolism. Coculture of AML cells and
BMSCsupregulates themitochondrial proteinsBCL2andUCP2,which
modify cellular energy metabolism by uncoupling leukemic mitochon-
dria, suppressing ROS level, increasing the apoptotic threshold, and
supporting aerobic glycolysis (Warburg effect). The increased apoptotic
threshold resulting from decreased mitochondrial membrane potential
and reducedROS level canalsoprotectLSCs fromchemotherapy.141,142
A recent study has shown that BMSCs can modify LSCmetabolism by
directly transferring mitochondria to AML blasts in a cell-cell contact-
and endocytosis-dependent manner. Mitochondrial uptake by the
leukemic blasts increases their adenosine triphosphate production
and protects them from mitochondrial depolarization after chemo-
therapy, thereby providing a survival advantage.143
BMSCs cocultured with AML cells promote chemotherapy
resistance by increasing c-myc levels in AML cells, and c-myc
inhibition can rescue AML cells from microenvironment-mediated
drug resistance.144 Conditioned medium from BMSCs has been
shown to support Stat3 survival signaling in CML cells in response
to imatinib.145 Combining CML targeting by TKIs with the JAK2
inhibitor ruxolitinib can overcome resistance by blocking JAK/STAT
signaling activated by BMSC-derived cytokines.146 Evidence for
BMSC-induced chemotherapy resistance has been obtained mainly
from studies on AML and CML, but other cytokines produced by
BMSCs (including IL-6, FGF, and CXCL10) can also promote
JAK2V617F1 cell resistance to atiprimod. Cytokine neutralizing
antibodies may effectively restore apoptosis in Ph–MPN cells.147
Treating the AML subtype acute promyelocytic leukemia (APL)
with all-trans-retinoic acid induces LSC differentiation and improves
patient survival. Non-APL AML is unresponsive to differentiation
therapy, and APL patients eventually relapse.148 Several leukemic
cell–intrinsic resistance mechanisms have been identiﬁed, but
upregulation of the all-trans-retinoic acid–metabolizing enzyme
cytochrome P450 gene CYP26 by stromal cells contributes to
development of minimal residual disease.149 Likewise, CYP3A4
upregulation in stromal cells confers resistance during etoposide
treatment of AML.150
The understanding of niche-controlled resistance is still in its infancy,
and despite the continuous development of novel treatment options,
evading resistance mechanisms might arise. An important additional
challenge is to avoid the elimination of normal HSCs. Therefore,
identifying factors released by tumor cells that trigger resistance
mechanisms conferred by niche cells is of importance to eventually
interfere with disease relapse (Figure 3). Development of more selective
drugs that act only on the mutated hematopoietic cells and/or combined
treatment targeting not only the mutated cells but also the microenvi-
ronmentmight improve the outcome.However, the therapeutic strategies
targeting the microenvironment should discriminate phases of normal
HSPC niche damage vs advanced niche transformation. At early-stage
disease and/or to diminish the damage caused by chemotherapy on
normal niches, preventive strategies aiming at protecting the normal
microenvironmentmight boost normal hematopoiesis andhelp to control
preleukemic cells. However, at advanced disease stages, when the
microenvironment has been profoundly transformed to support
leukemogenesis, different niche-targeting strategies will be needed.
Future directions
Signiﬁcant progress over the past few years has revealed important
roles of the BM microenvironment in the pathogenesis of mye-
loid malignancies. However, the underlying mechanisms are only
beginning to be elucidated, and an increasing complexity is becoming
apparent, with different roles in distinct diseases and disease stages.
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Therefore, caution should be taken when extrapolating conclusions.
Future focus on the complex interaction of neoplastic and microen-
vironmental cells will improve the development of niche-targeting
strategies. Important questions remain for the future. For instance, do
LSCs reside within speciﬁc niches? Do they interact with speciﬁc cell
types? And are these cell types different from those interacting with
normalHSCs?Doother cells regulating normalHSCs also play a role
in leukemogenesis? Immune cells such as macrophages play key
roles in the microenvironment of solid tumors and lymphoid
malignancies, but their contribution to the myeloid malignancies
remains much less explored. Do distinct niches for progenitor
cells contribute to speciﬁc subtypes of malignancies? Are there
key niche alterations during leukemogenesis leading to leukemic
transformation (from preleukemia to leukemia)? Do somatic
mutations in nonhematopoietic cells contribute to hematologic
malignancies and how? Adjuvant therapies targeting the contri-
bution of the microenvironment to leukemogenesis and resistance
will likely be needed to fully eradicate LSCs. However, rational
design of novel treatment strategies ﬁrst requires proper under-
standing of the normal niches and their alterations in myeloid
malignancies. Because the incidence of these diseases increases
with age, parallel study of the aging process is of major importance.
The reduced tolerance to chemotherapy, which contributes to the
increased lethality of myeloid malignancies in the elderly, might be
partially the result of impaired niche recovery during aging.
The current state-of-the art literature highlights the importance of
the BM niche in contributing to myeloid malignancy progression by
inducing or facilitating disease development, as well as conferring
resistance tochemotherapy.Theemerging recognitionof theenvironment
as a crucial player in multiple steps of the leukemic cascade lays the
foundation for tackling leukemia fromadifferent angle to improvecurrent
treatments.
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